






All admissions
2015-2023
(n=71,509)
Respiratory infection
diagnoses
Viral panel tested
(n=7,530)
Single infection
(n=2,085)
Omicron
(n=211)
RSV
(n=424)
HRV
(n=824)
HADV
(n=136)
HPIV
(n=343)
HMPV
(n=147)


100
80
60
40
20
0
LRTI (%)
12
10
8
6
4
2
0
Upper Airway Obstruction (%)
46.0%
9.5%
66.3%
0.2%
59.1%
1.3%
Omicron
RSV
HRV



Omicron
(n=211)
RSV
(n=424)
HRV
(n=824)
Percentage (%)
20.0
17.5
15.0
12.5
10.0
7.5
5.0
2.5
0.0
5.2%
4.3%
17.1%
11.8%
0.9%
1.4%
1.7%
1.7%
0.1%
0.6%
1.1%
1.7%
Febrile seizure
Afebrile seizure
Encephalo-pathy
Severe neuro


Omicron vs RSV
LRTI
Ventilator
MODS≥2
Inflammatory storm≥2
Neuro severe
Severe adverse
Death
0.76
1.39
3.80
3.89
5.81
3.08
4.00
0
2
4
6
8
10
12
Risk Ratio
Omicron vs HRV
LRTI
Ventilator
MODS≥2
Inflammatory storm≥2
Neuro severe
Severe adverse
Death
0.81
2.80
4.50
5.00
6.70
3.85
5.60
0
2
4
6
8
10
12
Risk Ratio


Omicron
0-1y (n=65)
1-3y (n=27)
3-6y (n=32)
6-18y (n=87)
10.8
9.2
6.5
6.5
3.2
6.5
33.3
25.9
16.7
22.2
22.2
16.7
6.2
15.6
18.8
21.9
15.6
25.0
2.3
27.6
12.2
14.3
12.2
10.2
UAO
Non-feb neuro
MODS≥2
Storm≥2
Neuro Sev
Sev Adverse
Percentage (%)
0
5
10
15
20
25
30
35
RSV
0-1y
1-3y
3-6y
6-18y
0.0
3.2
4.4
4.9
2.7
5.5
1.0
4.0
1.0
1.0
1.0
2.1
0.0
3.8
2.9
2.9
1.9
3.8
0.0
4.5
4.9
3.7
1.2
6.1
UAO
Non-feb neuro
MODS≥2
Storm≥2
Neuro Sev
Sev Adverse
Percentage (%)
0
5
10
15
20
25
30
35


LRTI
Non-febrile neuro
MODS≥2
UAO
Ventilator
Percentage (%)
60
50
40
30
20
10
0
Wave 1
(2022Q4)
n=100
Wave 2
(2023Q1-Q2)
n=94
Wave 3
(2023Q3-Q4)
n=17

Temporal Trends in Clinical Outcomes Across Wave Periods
(Children ≥6 months without malignancy)



Immune Exposure and Age-Specific Phenotypes of Pediatric Omicron Infection

